Kelsey Lewis
Nurse Practitioner · Wellsville, KSNPI 1346618998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,263 and has fallen 70.2% since, to $376 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$679
- Lilly USA, LLC$504
- AstraZeneca$490
- Novo Nordisk$463
- Boehringer Ingelheim$408
- E.r. Squibb & Sons, L.L.C.$93
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,664 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 40 | $62,634 |
| BotoxOnabotulinumtoxina | 41 | $53,610 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $20,494 |
| LinzessLinaclotide | 15 | $15,693 |
| JardianceEmpagliflozin | 12 | $15,629 |
| FarxigaDapagliflozin Propanediol | 15 | $15,615 |
| XareltoRivaroxaban | 20 | $15,585 |
| OzempicSemaglutide | 14 | $15,245 |
| EliquisApixaban | 16 | $9,739 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,405 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $2,612 |
| Levemir FlexpenInsulin Detemir | 11 | $1,797 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,672 |
| Duloxetine Hcl | 37 | $901 |
| Atorvastatin Calcium | 69 | $500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Linzess | $679 | $69,30456 claims |
| Lilly USA, LLCMounjaro | $504 | $62,63440 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $490 | $36,10939 claims |
| Boehringer IngelheimJardiance | $408 | $15,62912 claims |
| Johnson & JohnsonXarelto | $83 | $15,58520 claims |
| Novo NordiskOzempic | $463 | $15,24514 claims |
| GSKBreo Ellipta | $80 | $4,40511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Wellsville
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
- Kelli BradburyTopeka$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.